Inhibition of Restenosis in Femoropopliteal Arteries
Top Cited Papers
Open Access
- 23 September 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 118 (13), 1358-1365
- https://doi.org/10.1161/circulationaha.107.735985
Abstract
Background— The success of percutaneous intervention in peripheral arterial disease is limited by restenosis. The aim of the present pilot study was to evaluate a novel method of local drug delivery. Methods and Results— This randomized multicenter study with blinded reading enrolled 87 patients in Rutherford class 1 to 4 with occlusion or hemodynamically relevant stenosis, restenosis, or in-stent restenosis of femoropopliteal arteries. Treatment was performed by either conventional uncoated or paclitaxel-coated balloon catheters. The primary end point was late lumen loss at 6 months. Secondary end points included restenosis rate, ankle brachial index, Rutherford class, target lesion revascularization, and tolerance up to >18 months. Before intervention, there were no significant differences in lesion characteristics such as reference diameter (5.3±1.1 versus 5.2±1.0 mm), degree of stenosis (84±11% versus 84±16%), proportion of restenotic lesions (36% versus 33%), and mean lesion length (5.7 cm [0.8 to 22.6 cm] versus 6.1 cm [0.9 to 19.3 cm]) between treatment groups. The 6-month follow-up angiography performed in 31 of 45 and 34 of 42 patients showed less late lumen loss in the coated balloon group (0.5±1.1 versus 1.0±1.1 mm; P =0.031). The number of target lesion revascularizations was lower in the paclitaxel-coated balloon group than in control subjects (3 of 45 versus 14 of 42 patients; P =0.002). Improvement in Rutherford class was greater in the coated balloon group ( P =0.045), whereas the improvement in ankle brachial index was not different. The difference in target lesion revascularizations between treatment groups was maintained up to >18 months. No adverse events were assessed as related to balloon coating. Conclusions— In this pilot trial, paclitaxel balloon coating caused no obvious adverse events and reduced restenosis in patients undergoing angioplasty of femoropopliteal arteries.This publication has 18 references indexed in Scilit:
- Reduction of Stenosis Due to Intimal Hyperplasia After Stent Supported Angioplasty of Peripheral Arteries by Local Administration of Paclitaxel in SwineInvestigative Radiology, 2007
- Sustained Benefit at 2 Years of Primary Femoropopliteal Stenting Compared With Balloon Angioplasty With Optional StentingCirculation, 2007
- Prevention of restenosis: is angioplasty the answer?Heart, 2007
- Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery:Long-term Results From the SIROCCO TrialJournal of Endovascular Therapy, 2006
- Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon CatheterThe New England Journal of Medicine, 2006
- Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral ArteryThe New England Journal of Medicine, 2006
- Robustness of Late Lumen Loss in Discriminating Drug-Eluting Stents Across Variable Observational and Randomized TrialsCirculation, 2005
- Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of RestenosisCirculation, 2004
- Inhibition of Restenosis in Stented Porcine Coronary ArteriesInvestigative Radiology, 2004
- Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery DiseaseCirculation, 2002